CTLA4 and neoplasm: To enhance the therapeutic efficacy of vaccines and immune checkpoint inhibitors, Song H, et al. developed an injectable PEG-b-poly(L-alanine) hydrogel for the co-delivery of a tumor vaccine including tumor antigens/GM-CSF and dual-immune-checkpoint inhibitors (anti-CTLA-4/PD-1 antibody).